TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed advanced RCC with predominantly clear-cell subtype with primary tumor resected~* At least one measureable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.~* Eastern Cooperative Oncology Group performance status 0 or 1~* Controlled hypertension~Exclusion Criteria:~* Prior treatment with systemic therapy for advanced RCC~* Prior adjuvant or neoadjuvant therapy if disease progression or relapse has occurred during or within 12 months after the last dose of treatment~* Prior treatment with any agent specifically targeting T-cell co-stimulation or checkpoint pathways~* Active seizure disorder or evidence of brain metastases, spinal cord compression, or carcinomatous meningitis~* Diagnosis of any non-RCC malignancy occurring within 2 years prior to the date of randomization except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix or low grade prostate cancer with no plans for treatment intervention~* In past 12 months: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack~* In past 6 months: deep vein thrombosis or pulmonary embolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose finding phase and dose expansion phase (Type: EXPERIMENTAL): To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants aged 18 to 65 years with established SLE. Participants must have active SLE, Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score of at least 2 points for musculoskeletal or mucocutaneous manifestations and history or presence at screening of positive anti-nuclear antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies.~* Enrolled participants must be treated with background SLE medications.~Exclusion Criteria:~* Participants with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and infection risks, history or presence of malignancy, history or presence of bone marrow or solid organ transplantation) or lactating or pregnant women.~* Participants with severe SLE disease or with clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cenerimod 0.5 mg (Part A) (Type: EXPERIMENTAL): Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
- Cenerimod 1 mg (Part A) (Type: EXPERIMENTAL): Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
- Cenerimod 2 mg (Part A) (Type: EXPERIMENTAL): Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
- Cenerimod 4 mg (Part B) (Type: EXPERIMENTAL): Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
- Matching placebo (Part A and B) (Type: PLACEBO_COMPARATOR): Capsules of matching placebo taken orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female attendees (age ≥18yo) of the Ubuntu HIV and ARV Clinic identified as eligible for the ARV programme will be invited to participate.~2. Willingness to participate~3. Able to engage in informed consent procedures~Exclusion Criteria:~1. Evidence of active TB or suspicion of active TB as determined by a symptoms screening algorithm.~2. Current TB chemotherapy ( TB treatment completed in the preceding 30 days will not be an exclusion)~3. Current or previous treatment of latent TB infection since HIV infection (any duration)~4. Current treatment with fluoroquinolones or other antibiotics with significant anti-tuberculous activity currently being used to treat TB in South Africa~5. Past reaction/intolerance to INH.~6. Acute hepatitis or existing Grade III-IV peripheral neuropathy.~7. Pregnancy or \< 6weeks post-partum period (Due to increased risk of hepatotoxicity).~8. Grade III or higher baseline abnormal liver function. (Note: toxicity grades are all according to ACTG toxicity tables for persons on ART).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.Isoniazid (INH) (Type: EXPERIMENTAL): A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
- 2. Placebo (Type: PLACEBO_COMPARATOR): A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a confirmed and documented diagnosis of adult-onset rheumatoid arthritis, for at least 12 weeks, according to the revised 2010 American College of Rheumatology- European League Against Rheumatism (ACR-EULAR) classification criteria, including at least one positive criteria among the following: Rheumatoid Factor (RF), Anti-Citrullinated Peptide Antibody (ACPA) or bone erosion;~* Swollen joint count (SJC) of ≥ 4 (28-joint count) and tender joint count (TJC) ≥4 (28-joint count) at screening;~* Patient with a moderate to severe disease activity score Disease Activity Score (28 joints) C-Reactive Protein \[DAS28 CRP\] ≥ 3.2 and C-reactive Protein (CRP) ≥ 5 mg/L (≥ 4.76 nmol)/L) at screening;~* Patient who had an inadequate response (IR), or failed either methotrexate (MTX) or/and anti- Tumor Necrosis Factor alpha (TNFα) therapy (both administered for at least 12 weeks before IR) or were intolerant to anti- TNFα therapy.~Exclusion Criteria:~* Patient with a known positive anti-double stranded deoxyribonucleic acid (DNA \[anti-dsDNA\]) and confirmed diagnosis of systemic lupus erythematosus (SLE);~* Patient with known active infections at screening such as CytoMegaloVirus (CMV), herpes virus and/or recent infectious hospitalization;~* Acute, chronic or history of clinically relevant pulmonary, cardiovascular, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable Central Nervous System (CNS) pathology such as seizure disorder, angina or cardiac arrhythmias, active malignancy or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history;~* Acute, chronic or history of immunodeficiency or other autoimmune disease;~* Patient previously treated with any non-anti-TNF biological Disease-Modifying AntiRheumatic Drugs (bDMARDs), and targeted DMARDs (tDMARDS) prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABX464 50mg + methotrexate (Type: EXPERIMENTAL): Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks~+ methotrexate
- ABX464 100mg + methotrexate (Type: EXPERIMENTAL): Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks~+ methotrexate
- Placebo + methotrexate (Type: PLACEBO_COMPARATOR): Participants will receive two capsules of matching placebo once daily for 12 weeks~+ methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CANCER PATIENT: Age 18 years old or older (no upper limit)~* CANCER PATIENT: English speaking~* CANCER PATIENT: Diagnosed with stage Tis, Ta, or T1 bladder cancer~* CANCER PATIENT: Resides in the Western New York catchment area~* CANCER PATIENT: Did not receive a partial or radical cystectomy~* CANCER PATIENT: Does not have a prior cancer diagnosis within 12 months of their bladder cancer diagnosis~* CANCER PATIENT: Does not have a subsequent more advanced bladder cancer diagnosis~* CANCER PATIENT: For Roswell Park Cancer Registry only: Bladder cancer diagnosed 2016-2018, 2019-current~* CANCER PATIENT: Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.~* PHYSICIAN: English speaking~* PHYSICIAN: Physician in a clinic located in the catchment area~* PHYSICIAN: Currently treats bladder cancer patients~Exclusion Criteria:~* CANCER PATIENT: Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier~* CANCER PATIENT: Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events~* CANCER PATIENT: Adults unable to consent~* CANCER PATIENT: Adults unable to complete study measures in English~* CANCER PATIENT: Individuals who are not yet adults (infants, children, teenagers)~* CANCER PATIENT: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* CANCER PATIENT: Unwilling or unable to follow protocol requirements~* PHYSICIAN: Unable to complete the study measures in English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm A (Experimental arm) (Type: EXPERIMENTAL): 6-month Cruciferae intervention
- Arm B (Control arm) (Type: ACTIVE_COMPARATOR): 6-month fruit and vegetable intervention based on NCI guidelines for cancer survivors

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 2 months (56 to 98 days) at time of enrollment.~* Healthy infant as determined by medical history, physical examination, and judgment of the investigator.~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib conjugate vaccines.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Allergy or contraindication to paracetamol or ibuprofen administration.~* Contraindication to vaccination with pneumococcal conjugate, diphtheria, tetanus, pertussis, polio, Hib, or HBV vaccines.

- Gender: ALL
- Minimum Age: 56 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
- Group 2 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
- Group 3 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
- Group 4 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
- Group 5 (Type: EXPERIMENTAL): Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive breast cancer~  * Early-stage disease~    * No metastatic disease~ * Complete surgical excision of tumor~* Planned use of adjuvant chemotherapy and radiotherapy~* If participating in the cosmetic outcome evaluation portion of the study, must have unilateral disease~* Hormone receptor status~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* Not specified~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Bone marrow function adequate~Hepatic:~* Hepatic function adequate~Renal:~* Renal function adequate~Cardiovascular:~* Cardiac function adequate~Other:~* No other prior malignancy except basal cell or squamous cell skin cancer or carcinoma in situ~* No other medical or social condition that would preclude study compliance~* Fit to receive both adjuvant chemotherapy and radiotherapy (administered either synchronously or sequentially)~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* No prior chemotherapy~* No concurrent epirubicin and doxorubicin as a study combination chemotherapy regimen~Endocrine therapy:~* Prior or concurrent hormonal therapy allowed~* No concurrent tamoxifen if treated with methotrexate, mitomycin, and mitoxantrone as a study combination chemotherapy regimen~Radiotherapy:~* See Disease Characteristics~* No concurrent internal mammary chain irradiation~* No concurrent orthovoltage irradiation to the whole breast~Surgery:~* See Disease Characteristics~* Recovered from prior surgery~Other:~* Concurrent participation in another clinical trial allowed

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of NovoSeven® in Haemophilia - Joint Bleeds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hemophilia A or B with inhibitors to factor VIII or IX, respectively

- Gender: MALE
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Effects of a Spinal Mobilisation Intervention in People With Lower Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suffering from lower back pain (region between 12th rib and gluteal folds), acute or chronic.~Exclusion Criteria:~Respond positively to any absolute contraindications for spinal therapy, including:~* segment instability~* infectious disease~* osteomyelitis~* bone tumours~* neurological deficit~* upper motor neuron lesion~* spinal cord damage~* cervical arterial dysfunction~Respond positively to relative contra-indications, excluded based on severity, including:~* osteoporosis~* spinal instability~* rheumatoid arthritis~* inflammatory disease~* active history of cancer~* hypermobile syndrome~* segment hypermobility~* cardiovascular disease~* cervical anomalies~* nerve root disorder~* spinal surgery~* respiratory problems~* thrombosis~* open wounds~* local infection~* fractures or dislocations

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- A - Intervention then control (Type: EXPERIMENTAL): Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
- B - Control then intervention (Type: EXPERIMENTAL): Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>/=18 years~* Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)~* Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria~* Total Cumulative Illness Rating Scale (CIRS) \> 6 and/or creatinine clearance \< 70 ml/min~Exclusion Criteria:~* Prior CLL therapy~* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)~* History of other malignancy unless the malignancy has been in remission without treatment for \>/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone~* Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing~* Patients with active infection requiring systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- obinutuzumab + chlorambucil (GClb) (Type: EXPERIMENTAL): Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
- rituximab + chlorambucil (RClb) (Type: ACTIVE_COMPARATOR): Participants received 375 mg/m\^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
- Chlorambucil (Clb) (Type: ACTIVE_COMPARATOR): Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete